Home » EU Expands CE Mark for Dako Companion Diagnostics
EU Expands CE Mark for Dako Companion Diagnostics
Agilent Technologies has receive an expanded CE mark for its Dako PD-L1 IHC 22C3 pharmDx which can now be used to determine PD-L1 expression status to inform the first-line treatment of metastatic non-small cell lung cancer patients with Keytruda.
The intended use allows PD-L1 IHC 22C3 pharmDx to detect PD-L1 expression in both untreated and previously treated metastatic patients.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May